Compare CRMT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | VYGR |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 236.0M |
| IPO Year | 2026 | 2015 |
| Metric | CRMT | VYGR |
|---|---|---|
| Price | $12.46 | $3.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $29.50 | $21.00 |
| AVG Volume (30 Days) | 197.3K | ★ 900.2K |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | $33.19 |
| Revenue Next Year | $4.57 | $14.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.04 | $2.65 |
| 52 Week High | $62.55 | $5.55 |
| Indicator | CRMT | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 48.30 |
| Support Level | $11.04 | $3.72 |
| Resistance Level | $13.87 | $4.30 |
| Average True Range (ATR) | 0.95 | 0.21 |
| MACD | 0.31 | -0.02 |
| Stochastic Oscillator | 47.53 | 51.75 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.